See more : ThermoGenesis Holdings, Inc. (THMO) Income Statement Analysis – Financial Results
Complete financial analysis of MeiraGTx Holdings plc (MGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MeiraGTx Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Klabin S.A. (KLBN3.SA) Income Statement Analysis – Financial Results
- Interpharm Holdings, Inc. (IPAH) Income Statement Analysis – Financial Results
- WWPKG Holdings Company Limited (8069.HK) Income Statement Analysis – Financial Results
- Pacific Bay Minerals Ltd. (PBMFF) Income Statement Analysis – Financial Results
- Gram Car Carriers ASA (G39.BE) Income Statement Analysis – Financial Results
MeiraGTx Holdings plc (MGTX)
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.02M | 15.92M | 37.70M | 15.56M | 13.29M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 8.72M | 7.87M | 0.00 | 0.00 | 2.05M | 679.18K | 243.08K |
| Gross Profit | 14.02M | 7.20M | 29.83M | 15.56M | 13.29M | -2.05M | -679.18K | -243.08K |
| Gross Profit Ratio | 100.00% | 45.21% | 79.12% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 103.79M | 85.73M | 67.13M | 33.91M | 24.88M | 33.62M | 22.36M | 14.04M |
| General & Administrative | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Other Expenses | 0.00 | 361.00K | -434.00K | 0.00 | 0.00 | 83.08K | -553.50K | 0.00 |
| Operating Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Cost & Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Interest Income | 2.27M | 777.00K | 212.00K | 1.28M | 370.60K | 53.41K | 26.07K | 32.07K |
| Interest Expense | 13.25M | 4.95M | 288.00K | 139.20K | 48.61K | 33.43K | 42.86K | 25.44K |
| Depreciation & Amortization | 13.73M | 8.72M | 7.87M | 4.17M | 3.35M | 2.05M | 679.18K | 243.08K |
| EBITDA | -57.05M | -115.95M | -71.40M | -53.68M | -51.35M | -78.10M | -31.01M | -19.82M |
| EBITDA Ratio | -407.02% | -725.99% | -193.58% | -393.75% | -435.58% | 0.00% | 0.00% | 0.00% |
| Operating Income | -137.06M | -116.36M | -73.19M | -62.55M | -58.27M | -78.10M | -31.68M | -20.06M |
| Operating Income Ratio | -977.82% | -730.87% | -194.14% | -401.94% | -438.37% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 53.03M | -13.26M | -6.37M | 4.56M | 3.52M | -5.24M | 640.19K | 272.17K |
| Income Before Tax | -84.03M | -129.62M | -79.56M | -57.99M | -54.75M | -83.34M | -31.04M | -19.79M |
| Income Before Tax Ratio | -599.46% | -814.16% | -211.03% | -372.63% | -411.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.26M | -7.59M | -4.03M | -2.19M | -474.39K | -510.64K | -280.44K |
| Net Income | -84.03M | -142.88M | -71.98M | -53.96M | -52.56M | -82.87M | -31.04M | -19.49M |
| Net Income Ratio | -599.46% | -897.46% | -190.91% | -346.72% | -395.40% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| EPS Diluted | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| Weighted Avg Shares Out | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
| Weighted Avg Shares Out (Dil) | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
Week 17 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
Source: https://incomestatements.info
Category: Stock Reports